Quick Answer
Tenaya Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $100.55 million for the year ending 2025.
- Tenaya Therapeutics, Inc. showed an increase of +2,225.9% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Tenaya Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 11, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $40.34 million | Q3 2020: $61.34 million | Q1 2021: $128.44 million | Q2 2021: $111.89 million | Q3 2021: $117.08 million | Q1 2022: $25.97 million | Q2 2022: $31.01 million | Q3 2022: $34.49 million | Q1 2023: $72.54 million | Q2 2023: $75.57 million | Q3 2023: $82.15 million | Q1 2024: $59.30 million | Q2 2024: $58.13 million | Q3 2024: $8.23 million | Q1 2025: $53.77 million | Q2 2025: $62.67 million | Q3 2025: $56.31 million.
- Over the full 6 years of available data (2020 to 2025), Tenaya Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 21.8%.
- Historical annual values: Fiscal year 2025: $100.55 million | Fiscal year 2024: $4.32 million | Fiscal year 2023: $45.68 million | Fiscal year 2022: $95.27 million | Fiscal year 2021: $38.13 million | Fiscal year 2020: $128.54 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: